Osteoviva (Ibandronic Acid Monosodium Salt, Monohydrate)

Ibandronic Acid Monosodium Salt, Monohydrate, the active ingredient in Osteoviva, is a bisphosphonate presented as a intravenous solution for intravenous use. It treats osteoporosis in postmenopausal women and men at risk of fracture. GNH USA supplies Osteoviva as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Osteoviva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Osteoviva is a bisphosphonate that acts on bone metabolism to reduce fracture risk.

- Post‑menopausal osteoporosis: improves the bone mineral density and lowers the incidence of vertebral fractures. - Male osteoporosis: helps the increase the bone mass and reduces fracture incidence. - Glucocorticoid‑induced risk of fracture in patients with chronic steroid therapy :   -   -  

S     

S ​